Xcout Intel
リプロセル
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Subscribe to see リプロセル’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
リプロセル at a glance
リプロセル is a biotech company headquartered in Yokohama, Japan. It is publicly listed (4978) with a market capitalisation of $94.1M. Xcout tracks 9 named people at リプロセル, including Chikafumi Yokoyama (Chief Executive Officer, REPROCELL, Inc.).
リプロセル leadership
- Chikafumi YokoyamaChief Executive Officer, REPROCELL, Inc.
- Daisuke UsuiCOO, REPROCELL Inc. CEO, Bioserve Biotechnologies India, Pvt. Ltd.
- Karen BinghamCOO, REPROCELL Europe Ltd.
- David BuntonCEO, REPROCELL Europe Ltd.
- Rama ModaliCEO, REPROCELL USA Inc.
- Hiromitsu NakauchiProfessor and Director, Center for Stem Cell and Regenerative Medicine, Institute of Medical Science, The University of Tokyo
3 more named people on record for リプロセル, with roles, board committees and tenure — see the full roster →
リプロセル competitors
A few of リプロセル's closest competitors — see the full list of competitors and alternatives →
Accelerated Biosciences provides human trophoblast stem cell (hTSC) platforms, intellectual property, protocols, and starting materials to biopharma companies and research institutions. The company aims to support partners in developing novel regenerative medicine products, cell therapies, and immunotherapies.
InSphero provides 3D in vitro cell culture models, microplates, organ-on-a-chip platforms, and related services for drug discovery and safety testing. The company serves pharmaceutical, biotechnology, and research organizations seeking non-animal testing alternatives to evaluate drug efficacy, liver safety, oncology, and other complex diseases.
Axol Bioscience is a leading provider of iPSC-derived cells and related services, supporting neuroscience, ophthalmology, and cardiotoxicity drug discovery with advanced human disease models.
Deep Cell Industries Inc. provides an AI-integrated platform called REM-I that combines label-free imaging, deep learning, and cell enrichment for single-cell morpholomic analysis. The company serves researchers and organizations in oncology, drug discovery, cell and gene therapy, and related life science fields by enabling high-resolution profiling and sorting of viable cells.
Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.
Hubrecht Organoid Technology (HUB) develops patented patient-derived organoid technology from healthy and diseased tissues to predict patient responses to treatments. The company functions as a contract research organization (CRO), offering drug discovery services, custom model and assay development, clinical trials in a dish, and licensing programs for pharmaceutical and research applications.
Get リプロセル's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on リプロセル in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access